Quantifying Exposure to Engineered Nanomaterials from Manufactured Products (QEEN II) Workshop

Environmental, health, and safety (EHS) research continues to push the boundaries in characterizing and quantifying human and environmental exposures to engineered nanomaterials from manufactured products. The 2nd Quantifying Exposure to Engineered Nanomaterials from Manufactured Products (QEEN II) Workshop highlights new research on the tools and methods available to characterize and quantify effective population exposures, as well as the presence and release potential of nanomaterials. This two-day technical workshop builds on key themes that emerged from the first QEEN workshop in 2015. The QEEN II program will address the progress in integrating exposure, hazard, and risk to reduce uncertainties in nanomaterial EHS assessments. The workshop goals also include the identification of priorities and options for cross-disciplinary research collaborations. The intended audience includes academics, Federal representatives, and manufacturers and distributors of nanotechnology-enabled products, as well as communities seeking to understand exposure science related to engineered nanomaterials.

Registration: This workshop is free and open to the public with registration on a first-come, first-served basis. Registration will be capped at 180 attendees. Registration will open on July 9, 2018.

Graduate Student and Postdoc Travel Support: The organizing committee is pleased to provide travel assistance for a limited number of graduate students and postdoctoral associates to attend the meeting. More information is available here.

Questions? Email us at QEEN2workshop@nnco.nano.gov.

RTNN’s Dr. David Berube to serve on FDA’s Risk Communication Advisory Committee

We are excited to announce that RTNN’s Dr. David Berube will serve as a member on the Risk Communication Advisory Committee for the Food and Drug Administration (FDA) beginning this October and spanning into the next administration. As a committee member, Dr. Berube will advise the FDA Commissioner on strategies to effectively communicate the risks and benefits of FDA-regulated products to the public. The committee is also tasked with reviewing and evaluating relevant research and facilitating the implementation of public communication programs.